US EditionPublished • loading... • Updated
Medtronic (Nyse: Mdt) Receives Cms Ncd Coverage for Symplicity Spyral Renal Denervation
- The Centers for Medicare & Medicaid Services released a final National Coverage Determination for the Symplicity Spyral renal denervation system, also called the Symplicity blood pressure procedure.
- This coverage allows Medicare patients to access the Symplicity procedure for treating uncontrolled hypertension.
- Medtronic expressed pleasure with the final coverage determination, stating it opens up patient access to a safe and durable procedure.
- Hypertension is identified as the leading modifiable cause of heart attack, stroke, and death globally.
Insights by Ground AI
42 Articles
42 Articles
CMS Finalizes National Coverage Determination for Renal Denervation Systems
October 29, 2025—The Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation (RDN). Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately announced the action. The NCD is applicable to Medtronic’s Symplicity Spyral radiofrequency RDN system and Recor’s Paradise ultrasound renal denervation (uRDN) system for the treatment of …
CMS finalizes national coverage for Medtronic’s Symplicity Spyral RDN, enabling Medicare access for uncontrolled hypertension; FDA approved Nov 2023.
Coverage Details
Total News Sources42
Leaning Left4Leaning Right2Center15Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 19%
C 71%
Factuality
To view factuality data please Upgrade to Premium
